Omicron News and Research

RSS

Impact of COVID-19 booster vaccination and breakthrough infection

Researchers assessed the protection elicited after a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccination or a breakthrough infection against SARS-CoV-2 Omicron variant infection.

5 Dec 2022

SARS-CoV-2 Omicron infections pose long-COVID risks despite reduced severity

researchers compared the post-coronavirus disease complaints and symptoms in individuals infected with the SARS-CoV-2 Omicron variant with those in individuals with Delta variant infections to understand whether the long-term complaints after Omicron infections are similar to those in infections with other SARS-CoV-2 variants.

2 Dec 2022

Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

Researchers from the United States developed an affordable, non-invasive, inhalable prophylactic treatment consisting of immunoglobulin (Ig) A fused nanobodies against the SARS-CoV-2 Omicron variant.

2 Dec 2022

Primary and original booster mRNA vaccination can reduce the risk of Omicron-related infection

mRNA COVID-19 vaccines are less effective against Omicron infections than other variants. A study publishing December 1st in the open access journal PLOS Medicine by Margaret L. Lind at the Yale School of Public Health, U.S. and colleagues suggests that the additional protection offered by the initial booster shot may be reduced among people with a previous COVID-19 infection.

1 Dec 2022

Human T cell immunity is coping with mutations in SARS-CoV-2 variants of concern

Immune T cells are continuing to target the spike protein of SARS-CoV-2 variants of concern, although mutations are making some T cells less effective, according to new research.

1 Dec 2022

Prior infection and vaccination protects against severe outcomes from SARS-CoV-2 Omicron infection

Previous infection with SARS-CoV-2 and booster vaccination protect against ICU admission and mortality following infection with the Omicron variant.

1 Dec 2022

Are medical masks non-inferior to N95 respirators to prevent COVID-19 in health care workers providing routine care?

Researchers determined whether medical masks were non-inferior to N95 respirators in preventing a SARS-CoV-2)infection in healthcare workers.

1 Dec 2022

Novel prefusion S antigen designed by the mutation of the SARS-CoV-2 Spike protein’s trimeric structure

Researchers mutated the SARS-CoV-2 spike protein's trimeric structure to design a novel prefusion S antigen, S2D14.

1 Dec 2022

The requirement for Fc effector functions to protect against SARS-CoV-2 infection

Researchers determined which specific fragment crystallizable effector functions protect against SARS-CoV-2 infection, especially its emerging variants.

1 Dec 2022

Detection of early-formed, antigen-specific clones in SARS-CoV-2-reactive B cells after longitudinal analysis

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, has globally infected more than 639 million individuals and claimed over 6.6 million lives. Despite the rapid commencement of COVID-19 vaccination programs in most countries across the world, the virus has remained in circulation.

30 Nov 2022

Study shows SARS-CoV-2 VOCs disseminated around the world according to different spatial source-sink dynamics

Researchers assessed the dispersion patterns of SARS-CoV-2 variants and their global expansion.

30 Nov 2022

The effect of evolutionary changes in prolonged SARS-CoV-2 infection in an immunosuppressed individual due to advanced HIV

Researchers assessed the impact of SARS-CoV-2 infection on cell death and fusion in an immunocompromised host.

30 Nov 2022

Plasma from vaccinated and COVID-19 convalescent subjects as passive immunotherapy against the new Omicron BQ.1.1, XBB, and BF.7 variants

Researchers systematically reviewed SARS-CoV-2 Omicron BQ.1.1 neutralization data from individual patient samples.

30 Nov 2022

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

A recent study identified neutralizing antibodies against conserved SARS-CoV-2 epitopes.

30 Nov 2022

The antibody resistance profile and viral receptor binding affinity of SARS-CoV-2 Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants

Researchers investigated the neutralizing antibody titers against the newly emergent BQ.1, BQ.1.1, XBB, and XBB.1 SARS-CoV-2 Omicron subvariants using sera from individuals with primary and booster COVID-19 vaccinations and previous SARS-CoV-2 infections.

30 Nov 2022

The evolutionary trajectories and mechanisms driving the emergence of post-Omicron SARS-CoV-2 lineages

Researchers summarized the mechanisms through which the SARS-CoV-2 new Omicron sublineages are evolving.

30 Nov 2022

Engineered proteins can be delivered as a nasal spray to protect against and treat COVID-19

COVID-19 has had a lasting global health impact that continues to challenge the health care system. As the coronavirus continues to mutate, the current COVID-19 prevention strategies are plagued with supply chain disruptions, high vaccine manufacturing costs and inconvenient vaccine administration methods.

29 Nov 2022

COVID-19 boosters and updated vaccines are more important for older adults, study suggests

The Pfizer-BioNTech COVID-19 vaccine limits transmission, hospitalization, and death from COVID-19 even among patients infected by variants of the virus, but the effectiveness of antibodies it generates diminishes as patients get older, according to a study by UT Southwestern researchers.

29 Nov 2022

SARS-CoV-2 Omicron variant tends to spread more easily among children than prior strains

Researchers estimate the age-varying susceptibility to infection with the SARS-CoV-2 Omicron variant.

28 Nov 2022

Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron

Isolated monoclonal antibodies neutralize SARS-CoV-2 Delta and Omicron variants.

28 Nov 2022

Omicron News and Research

Impact of COVID-19 booster vaccination and breakthrough infection

SARS-CoV-2 Omicron infections pose long-COVID risks despite reduced severity

Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

Primary and original booster mRNA vaccination can reduce the risk of Omicron-related infection

Human T cell immunity is coping with mutations in SARS-CoV-2 variants of concern

Prior infection and vaccination protects against severe outcomes from SARS-CoV-2 Omicron infection

Are medical masks non-inferior to N95 respirators to prevent COVID-19 in health care workers providing routine care?

Novel prefusion S antigen designed by the mutation of the SARS-CoV-2 Spike protein’s trimeric structure

The requirement for Fc effector functions to protect against SARS-CoV-2 infection

Detection of early-formed, antigen-specific clones in SARS-CoV-2-reactive B cells after longitudinal analysis

Study shows SARS-CoV-2 VOCs disseminated around the world according to different spatial source-sink dynamics

The effect of evolutionary changes in prolonged SARS-CoV-2 infection in an immunosuppressed individual due to advanced HIV

Plasma from vaccinated and COVID-19 convalescent subjects as passive immunotherapy against the new Omicron BQ.1.1, XBB, and BF.7 variants

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

The antibody resistance profile and viral receptor binding affinity of SARS-CoV-2 Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants

The evolutionary trajectories and mechanisms driving the emergence of post-Omicron SARS-CoV-2 lineages

Engineered proteins can be delivered as a nasal spray to protect against and treat COVID-19

COVID-19 boosters and updated vaccines are more important for older adults, study suggests

SARS-CoV-2 Omicron variant tends to spread more easily among children than prior strains

Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News